BioVie Inc. (OTCMKTS:BIVI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 14, 2017, the Board of Directors of BioVie Inc. (“BioVie”) appointed Julie G. Anderson as a member of the Board. Ms. Anderson is an experienced executive in the healthcare field, with particular experience as a healthcare provider in the field of liver diseases.
In connection with Ms. Anderson’s appointment to the Board, BioVie issued an option to purchase 100,000 shares of common stock to Ms. Anderson. The option may be exercised for $0.22 per share and has a term of two years. BioVie also agreed to pay cash in the amount of $30,000 to Ms. Anderson, payable over the course of six months.
––
About BioVie Inc. (OTCMKTS:BIVI)
BioVie, Inc., formerly NanoAntibiotics, Inc., is a development-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of drug therapies. The Company is focused on commercializing BIV201, which is used for the treatment of ascites due to liver cirrhosis. The Company’s therapy BIV201 is based on a drug that is approved in over 50 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites). The Company’s subsidiary is LAT Acquisition Corp. BioVie Inc. (OTCMKTS:BIVI) Recent Trading Information
BioVie Inc. (OTCMKTS:BIVI) closed its last trading session down -0.010 at 0.290 with shares trading hands.
